Sodium Excretion of LCZ696 in Patients With Hypertension; Heart Failure and Healthy Volunteers

• Status: Completed
• Trial end date: 2012-08-01
• Target enrollment: 0
• Participant gender: All

Summary

Assess mechanism of action of LCZ696 related to sodium excretion.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis Pharmaceuticals
• Treatments: LCZ 696; Sacubitril and valsartan sodium hydrate drug combination; Valsartan

Criteria

Inclusion Criteria:

• Patients with heart failure: documented NYHA class II-III heart failure

• Patients with hypertension: stable hypertensive medication for the preceding 2 months

Exclusion Criteria:

• Women of childbearing potential

• History of recent myocardial infarction

• History of dialysis or renal transplant

• Patients with type 1 diabetes mellitus